Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its participation in the TD Cowen 45th Annual Health Care Conference. Meg Alexander, President and Chief Operating Officer, will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts.
Investors and interested parties can access the live webcast through the Events & Presentations section at investors.ovidrx.com. A replay will remain available on the company's website for approximately 30 days after the presentation.
Ovid Therapeutics (NASDAQ: OVID), un'azienda biofarmaceutica focalizzata sullo sviluppo di medicinali per condizioni cerebrali, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. Meg Alexander, Presidente e Direttore Operativo, presenterà un intervento lunedì 3 marzo 2025, alle 15:10 ET a Boston, Massachusetts.
Gli investitori e le parti interessate possono accedere alla diretta del webcast attraverso la sezione Eventi & Presentazioni su investors.ovidrx.com. Una registrazione sarà disponibile sul sito web dell'azienda per circa 30 giorni dopo la presentazione.
Ovid Therapeutics (NASDAQ: OVID), una empresa biofarmacéutica centrada en el desarrollo de medicamentos para condiciones cerebrales, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. Meg Alexander, Presidenta y Directora de Operaciones, ofrecerá una presentación el lunes 3 de marzo de 2025, a las 3:10 p.m. ET en Boston, Massachusetts.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Eventos y Presentaciones en investors.ovidrx.com. Una repetición estará disponible en el sitio web de la empresa durante aproximadamente 30 días después de la presentación.
오비드 테라퓨틱스 (NASDAQ: OVID), 뇌 질환 치료제를 개발하는 생명공학 회사가 TD 코웬 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다. 메그 알렉산더 사장 겸 COO가 2025년 3월 3일 월요일 오후 3시 10분 ET에 매사추세츠주 보스턴에서 발표를 진행합니다.
투자자 및 관심 있는 분들은 investors.ovidrx.com의 이벤트 및 발표 섹션에서 라이브 웹캐스트에 접속할 수 있습니다. 발표 후 약 30일 동안 회사 웹사이트에서 다시 보기 서비스를 이용할 수 있습니다.
Ovid Therapeutics (NASDAQ: OVID), une entreprise biopharmaceutique axée sur le développement de médicaments pour des affections cérébrales, a annoncé sa participation à la 45ème Conférence Annuelle de Santé de TD Cowen. Meg Alexander, Présidente et Directrice des Opérations, fera une présentation le lundi 3 mars 2025, à 15h10 ET à Boston, Massachusetts.
Les investisseurs et les parties intéressées peuvent accéder au webcast en direct via la section Événements & Présentations sur investors.ovidrx.com. Un enregistrement sera disponible sur le site de l'entreprise pendant environ 30 jours après la présentation.
Ovid Therapeutics (NASDAQ: OVID), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Medikamenten für Hirnerkrankungen konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Meg Alexander, Präsidentin und Chief Operating Officer, wird am Montag, den 3. März 2025, um 15:10 Uhr ET in Boston, Massachusetts, eine Präsentation halten.
Investoren und Interessierte können über den Bereich Veranstaltungen & Präsentationen auf investors.ovidrx.com auf den Live-Webcast zugreifen. Eine Wiederholung wird etwa 30 Tage nach der Präsentation auf der Website des Unternehmens verfügbar sein.
- None.
- None.
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts.
A live webcast of the TD Cowen presentation can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 30 days.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that have the potential to modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, and a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders; and OV888/GV101, a highly selective ROCK2 inhibitor, for undisclosed neurovascular and neuro-inflammatory conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Investor Relations:
Garret Bonney
617-735-6093
gbonney@ovidrx.com
FAQ
When is Ovid Therapeutics (OVID) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Ovid Therapeutics' (OVID) TD Cowen conference presentation?
Who will represent Ovid Therapeutics (OVID) at the TD Cowen Healthcare Conference?
How long will Ovid Therapeutics' (OVID) TD Cowen conference presentation replay be available?
